1162695-95-5

Basic information

• Product Name: 5-broMo-N1-ethylbenzene-1,2-diaMine
• Synonyms: 5-broMo-N1-ethylbenzene-1,2-diaMine
• CAS NO: 1162695-95-5
• Molecular Formula: C₈H₁₁BrN₂
• Molecular Weight: 215.09034
• Mol File: 1162695-95-5.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-broMo-N1-ethylbenzene-1,2-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-broMo-N1-ethylbenzene-1,2-diaMine(1162695-95-5)
• EPA Substance Registry System: 5-broMo-N1-ethylbenzene-1,2-diaMine(1162695-95-5)

Safety Data

• Hazardous Substances Data: 1162695-95-5(Hazardous Substances Data)

Upstream product

• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 813448-98-5 5-bromo-N-ethyl-2-nitro-aniline 

Downstream Products

• 1447911-15-0 1-(2-cyclopropyl-1-ethyl-1H-benzimidazol-6-yl)-4-((4-fluorobenzyl)oxy)pyridin-2(1H)-one 
• 1447911-17-2 4-((4-chlorobenzyl)oxy)-1-(2-cyclopropyl-1-ethyl-1H-benzimidazol-6-yl)pyridin-2(1H)-one 

Relevant articles and documents

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3,R4, R5, R6, N-Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

HETEROCYCLIC KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.